DoctoRx
Contributor since: 2013
Articles
In Memory Of SA Contributor DoctoRx
Apr. 14, 2021 312 Comments
Final Market Comments (Goodbye To Seeking Alpha)
Editors' PickNov. 24, 2020 AAPL, AMZN, BMY308 Comments
Gilead: 'Failed' Remdesivir Solidarity Study Might Really Show Efficacy
Editors' PickOct. 18, 2020 GILD166 Comments
Lowe's Looks Poised To Keep Going Higher
Sep. 28, 2020 LOW37 Comments
UPS: New CEO, New Strategy To Deliver Sustainable Alpha
Editors' PickSep. 13, 2020 UPS53 Comments
Zoom: Total Available Market May Be Larger Than What Is Priced In
Sep. 8, 2020 ZM59 Comments
Tesla: How It Still May Deliver Sustainable Alpha
Editors' PickAug. 24, 2020 TSLA243 Comments
Nvidia: Why It's Still Early Innings
Editors' PickAug. 21, 2020 NVDA161 Comments
Long Zoom, Short NYC And LA
Editors' PickAug. 18, 2020 ZM99 Comments
Novo Nordisk: Long-Term Growth By CV Risk Factor Reduction
Aug. 17, 2020 NVO51 Comments
Biotech's Q2:  Lots Of Candidates That May Deliver Alpha
Editors' PickAug. 9, 2020 AZN, AZNCF, GILD69 Comments
Gilead: Perhaps A Value Trap No Longer
Editors' PickAug. 2, 2020 GILD97 Comments
Why Gold May Be In For A Fall This Summer
Editors' PickJul. 26, 2020 GDX, GOLD, NEM189 Comments
How COVID Panic Can Be Leading To A New 'Goldilocks' Scenario
Editors' PickJul. 20, 2020 AAPL, ACN, ADBE21 Comments
Tesla Says 'Catch Me If You Can' - But They Can't
Editors' PickJul. 13, 2020 TSLA291 Comments
Time To Look Beyond Today's Headlines
Editors' PickJul. 5, 2020 AMZN, GILD, MSFT64 Comments
Second COVID Wave? Analysis And Updated Investment Strategy
Editors' PickJun. 28, 2020 SPY, AMZN, COST197 Comments
Gold: Reasons To Stay Bullish On The Metal, And On Some Miners
Editors' PickJun. 22, 2020 GLD, GOLD, SLV38 Comments
Novo Nordisk: A Plan To Grow Into The 2030s
Editors' PickJun. 21, 2020 NVO54 Comments
Regeneron: Growth Plans In Immuno-Oncology (ASCO Update)
Jun. 8, 2020 REGN41 Comments
AstraZeneca: Surprise At ASCO May Mean New Highs Ahead
Editors' PickJun. 1, 2020 AZN26 Comments
NIH Study Supports Wide Use Of Gilead's Remdesivir In COVID-19
Editors' PickMay 25, 2020 GILD270 Comments
Gilead: Strategic Update - Focus On 'Defend/Extend' HIV Franchise
May 11, 2020 GILD108 Comments
Regeneron: Cancer, COVID, And More Could Be Breaking Its Way
May 7, 2020 REGN37 Comments
Gilead Reports (Part 1): Focus On Remdesivir For COVID-19
Editors' PickMay 4, 2020 GILD107 Comments
Why Gilead's COVID Drug May Be The Magic Bullet We Need
Editors' PickApr. 19, 2020 GILD1130 Comments
'Don't Fight The Fed' As The Wrong Strategy: A 2-3 Year Plan
Apr. 13, 2020 GILD, IAU, TLT158 Comments
Gold Is Good: Why I'm Adding In A Deflationary Meltdown
Apr. 6, 2020 GE, GLD, SLV123 Comments
Why There's Less To This Oil Price Rally Than Meets The Eye
Apr. 3, 2020 NEE, SPY, TLT127 Comments
3 Antifragile Stocks I'm Buying, And Why I'm Starting Now
Apr. 1, 2020 AAPL, AIG, AIG.PA163 Comments
Three Little Words For Bonds: Still A Buy
Mar. 2, 2020 JNJ, MSFT, TBT17 Comments
Markets That Try Men's Souls: Of Techs And Technicals
Mar. 2, 2020 AAPL, ACN, META38 Comments
Bouncing Biotechs: A Multi-Company Review
Feb. 24, 2020 ABT, ALXN, ELV56 Comments
Utilities: Making The Case That Their Rally Has More Juice Left
Feb. 24, 2020 XLU28 Comments
Nvidia On The Way To Dominance In Tomorrow's AI-Centric World
Feb. 18, 2020 NVDA107 Comments
Intuitive Surgical: High Growth Potential In Surgery, And Beyond
Feb. 17, 2020 ISRG69 Comments
Merck Spins, And Falls:  Why I Am More Bullish Than The Street
Feb. 13, 2020 MRK75 Comments
Novo Nordisk's Insulin Products, Pipeline May Energize The Stock
Feb. 12, 2020 NVO49 Comments
O'Day Making Gilead Good, And Perhaps Great Again
Feb. 10, 2020 GILD77 Comments
Vertex Beats: How A High P/E Biotech May Be Undervalued
Feb. 3, 2020 VRTX25 Comments